675 studies (9 from unattributed sources) on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Bfflist Amo | 247 | 99.61% | View COA → |
| Sry Labs | 207 | 99.55% | View COA → |
| Shanghai Sigma Audley Ssa | 140 | 99.56% | View COA → |
| Hk Peptides | 133 | 99.76% | View COA → |
| Allen Biotechnology Co Abc | 124 | 99.66% | View COA → |
| Planet Peptide | 105 | 99.76% | View COA → |
| Zlz Peptide | 94 | 99.72% | View COA → |
| GYC | 93 | 99.73% | View COA → |
Recent certificates: #27962 (99.94%) · #28001 (99.52%) · #30760 (99.98%) · #31566 (99.96%) · #42192 (99.69%) · #42719 (99.95%)
Manufacturers with published third-party certificates of analysis for Tirzepatide. Open a vendor to see every batch we've verified.
A Phase 1 pilot trial is underway to assess tirzepatide's effects on colorectal cancer risk biomarkers and evaluate the feasibility of precision prevention.
This real-world study will provide critical insights into **tirzepatide's effectiveness and safety profile** in a specific Latin American population, which can significantly influence clinical practice in Paraguay and…
**If successful, this study could establish a novel pharmacological approach for managing Alcohol Use Disorder (AUD)**, potentially offering a new treatment option for individuals struggling with alcohol cravings. Und…
This meta-analysis provides crucial reassurance for clinicians and patients regarding the short-to-medium term safety of incretin-based therapies concerning **thyroid cancer** risk. **For individuals using or consider…
This real-world comparative effectiveness study suggests that **Tirzepatide may offer superior protection against major adverse outcomes**—including mortality, liver, cardiovascular, and kidney events—compared to thia…
The widespread use of `GLP-1 RAs` demands a paradigm shift in clinical practice to safeguard patient mental health. **Routine eating disorder screening before and during GLP-1 RA treatment is now critical**, along wit…
This research unveils a novel mechanism by which **GIPR** and **GLP-1R** agonists, including dual agonists like tirzepatide, could modulate dopamine signaling in brain regions critical for reward and addiction. **The …
This case report underscores the clinical relevance of the FDA black box warning for GLP-1 receptor agonists like **tirzepatide** regarding **medullary thyroid cancer (MTC)** risk. While a single case cannot establish…
This case underscores the extreme complexity and high recurrence rate associated with massive **Type IV hiatal hernias**, particularly when compounded by multi-organ involvement and patient comorbidities. For clinicia…
**This comprehensive analysis reinforces GLP-1-based therapies as a cornerstone for managing Type 2 Diabetes with cardiovascular risk.** It provides critical agent-level insights, guiding clinicians in selecting speci…
This real-world data from Japan reinforces the robust efficacy of **tirzepatide** beyond controlled trial settings, providing crucial validation for its use in diverse patient populations. **For clinicians and patient…
This network meta-analysis provides crucial, evidence-based guidance for clinicians and individuals navigating the expanding landscape of anti-obesity medications. **Tirzepatide 15mg** and **CagriSema** are now clearl…
If the SURMOUNT-3 trial demonstrates positive results, it could significantly **redefine strategies for long-term weight loss maintenance** following lifestyle interventions. For individuals who have successfully lost…
This meta-analysis provides crucial insights for individuals using GLP-1RAs for weight management, particularly those concerned about body composition. **While GLP-1RAs are highly effective for fat loss, strategies to…
**Understanding the population-level impact of GLP-1/GIP receptor agonists** like semaglutide and tirzepatide is crucial for public health planning and resource allocation. If projections are substantial, this could i…
Dual `GIP`/`GLP-1` agonist **tirzepatide** achieved MACE non-inferiority vs. dulaglutide, slowed `eGFR` decline in **T2D**, and reduced heart failure events in **obesity** with `HFpEF`.
GLP-1 receptor agonists significantly reduced the risk of postoperative inflammatory complications like infection and wound disruption after dermatologic surgery.
Given the escalating use of **GLP-1RAs** for metabolic conditions and weight management, **dermatology practitioners and prescribing clinicians must be acutely aware of the potential association with alopecia**. This …
This review highlights that while **GLP-1 RAs** are not yet proven as direct treatments for lipedema progression, they hold significant promise as **adjunctive therapies**. For individuals with lipedema, who often str…
The comprehensive metabolic improvements observed with tirzepatide represent a significant leap forward for individuals managing **type 2 diabetes** and associated **cardiovascular risks**. **This dual GIP/GLP-1 agoni…
This meta-analysis provides critical head-to-head evidence for clinicians and individuals managing **obesity** and **type 2 diabetes**. **Tirzepatide offers superior weight loss compared to semaglutide**, which could …
This research offers a transformative approach to managing **obesity** and **Type 2 Diabetes** by potentially enabling dramatically less frequent dosing. **Patients could achieve sustained weight and glucose control w…
This head-to-head **tirzepatide** vs. **semaglutide** trial is crucial for clinicians and individuals seeking optimal pharmacotherapy for **obesity** and **overweight**. While both are highly effective, a direct compa…
A 52-week randomized controlled trial will assess **Tirzepatide** with a culturally-tailored intensive lifestyle intervention in Latino adults with obesity.
GLP-1 receptor agonists' pleiotropic effects on retinal microvasculature are reviewed, highlighting their potential to mitigate diabetic microangiopathy beyond glycemic control.
GLP-1 receptor agonists offer significant cardiometabolic benefits, addressing inflammation and metabolic disturbances in obesity-related heart failure with preserved ejection fraction (HFpEF).
Pancreatic **pVHL** gene therapy via adenoviral vector cut blood glucose in hypercaloric diet-induced **Type 2 Diabetes Mellitus** mice.
A promising new direction emerges for treating **MC4R**-related **obesity**, a condition with limited therapeutic options. **SKNY-1**'s ability to address both metabolic dysfunction and maladaptive reward behaviors su…
Insulin and incretin receptor agonists (IRAs) reciprocally influence each other's blood-brain barrier permeability, suggesting complex interactions at this critical interface.
Understanding the rewired `IL-10` signaling and transcriptomic landscape in **MASLD-associated HCC** offers crucial insights for future therapeutic strategies. **Identifying these specific molecular shifts could lead …
**Tirzepatide**'s potential to modify **obstructive sleep apnea (OSA)** beyond weight loss could revolutionize treatment paradigms. For individuals with **obesity-related OSA**, this suggests a future where pharmacolo…
Obesity significantly promotes cancer development by inducing chronic metaflammation, metabolic reprogramming, and immune evasion, impacting several cancer hallmarks.
**Tirzepatide** is being evaluated in a 72-week randomized, placebo-controlled trial for body weight reduction in participants with obesity or overweight.
**Combining bremelanotide with tirzepatide could offer a more potent and comprehensive strategy for obesity management**, potentially overcoming limitations of current monotherapies. For individuals struggling to achi…
This trial represents a significant step towards a novel, non-surgical treatment for **endometrial cancer** in overweight women. If successful, **Tirzepatide** could offer a critical option for **fertility preservatio…
**Preserving lean muscle mass during significant weight loss with GLP-1/GIP agonists is a critical health goal.** This trial aims to provide evidence on whether adding structured exercise to **semaglutide** or **tirze…
This preclinical study offers compelling evidence that **tirzepatide** could serve as a promising adjunctive therapy to enhance the cardiac safety profile of `DOX` chemotherapy. For clinicians, this opens a new avenue…
**Clinicians gain an updated, comprehensive perspective on the latest therapeutic options for Heart Failure**, integrating new pharmacotherapies, device strategies, and emerging biological approaches. This review help…
These findings offer a significant new perspective for managing **hepatic encephalopathy** in patients with cirrhosis. **GLP-1 RA therapy, specifically semaglutide or tirzepatide at weight-loss doses, may be a viable …
**Integrating tailored lifestyle interventions with OMMs is crucial for optimizing long-term patient outcomes and shifting obesity care towards a health-centered model.** For clinicians and patients, this means moving…
**Early intervention with tirzepatide offers significantly better and more durable glycemic control, weight loss, and waist circumference reduction than current standard-of-care intensification strategies in early T2D…
This real-world evidence suggests that **GLP-1RAs could be a valuable therapeutic strategy for primary stroke prevention and overall mortality reduction in patients with asymptomatic ICAS**, potentially expanding thei…
This network meta-analysis provides crucial, dosage-specific evidence for treating **MASLD** patients with F1-F3 fibrosis, a population with high unmet medical need. **Clinicians and biohackers can now consider specif…
This review underscores that **GLP-1-based therapies represent a promising, phenotypically targeted approach for managing obesity-associated HFpEF**, offering significant improvements in patient-centric outcomes like …
This review underscores a critical shift towards an **integrated, phenotype-driven approach** for managing cardiac arrhythmias in patients with obesity and OSA. For peptide users and clinicians, it highlights **tirzep…
This comprehensive review highlights a significant potential paradigm shift in the management of **obesity-related obstructive sleep apnea (OSA)**, suggesting that **tirzepatide** could offer true disease modification…
This review significantly strengthens the case for **GLP-1RAs** as a viable pharmacological strategy for **AUD**, offering a much-needed alternative to current limited treatments. For peptide users and clinicians, thi…
This review provides a critical roadmap for advancing **precision medicine** in **Tirzepatide** therapy. **Identifying these predictors could enable clinicians to personalize treatment strategies, optimize dosing, and…
This report provides crucial guidance for clinicians, particularly nurse practitioners, on navigating the complex landscape of `GLP-1` use. **Providers must proactively educate patients on the dangers of unregulated c…
**Clinicians and individuals using tirzepatide must prioritize individualized risk-benefit assessment**, especially given the noted high risk of severe gastrointestinal events and potential impact on skeletal muscle m…
Free, no account — handy when you're working with Tirzepatide.